Tag: venture capital

None Better than One? (A Brief Note on VC in Smaller Hubs)

Biotech venture funding metrics continue at historic highs, highlighting that the robust financing environment in the public markets continues to fuel the private markets as well.  – Bruce Booth, partner Atlas Venture in Data Snapshot: Venture-Backed Biotech Financing Riding High, April 2015 Here in Madison, Wisconsin, you might not know that was true if you

Read More

What is the optimal biotech burn rate?

Ethan Perlstein, founder of Perlstein Lab, asked a question on Twitter and got some great answers from David Grainger, partner at Index Ventures and Katrine Bosley, CEO of Editas Medicine. (You can read the whole thread by clicking through.) @LifeSciVC @sciencescanner @ksbosley @scientre what's the burn rate distribution of biotech NewCos in for the first year of

Read More

Could Pharma/Biotech Build an Amazon?

Pharma/Biotech Business Model Innovation When I hear/read about business model innovation in pharma/biotech, the themes generally focus on changes that would improve R&D productivity – moving discoveries from academia to industry more efficiently (some examples of university-related incubators), reproducibility of experiments, venture capital firms creating their own early stage companies, pharma moving R&D innovation external (corporate, biotech and

Read More

Biotech: Outside Looking In

In a post in March, I suggested that I would represent the “less glamorous side of things” in the biotech industry. This week gave me an opportunity to attempt that directly. Setting the Stage Earlier this year, Bruce Booth at Atlas Venture started a new thing – a great thing: having management from their biotech portfolio companies

Read More

(Re)Reading This Weekend (6/14/14)

There were a few long reads that I’ll be re-reading over the weekend, including: New blood  (at Fortune, by Roger Parloff @rparloff) This article profiles the blood diagnostics company, Theranos, and the founder, Elizabeth Holmes. While you will find the founder description interesting, I found myself drawn to the questions of business model, trade secrets and regulation.

Read More

Risk Distribution & Opportunity Costs in Entrepreneurship

Risk Distribution In WIRED, “One Startup’s Struggle to Survive the Silicon Valley Gold Rush” by  Gideon Lewis-Kraus is a very long read for a magazine article but works to compare/contrast the social and economic lives of tech startup founders and employees at larger tech companies. Here’s a passage that stuck with me for hours after reading the

Read More

Is Biotech Venture Capital Dying?

This post was inspired by the Xconomy story Wisconsin 2013 VC Activity Drops, Shifts to Software from Biotech. To recap, Wisconsin has historically fared very poorly by virtually any measure related to venture capital. And 2013 was ugly form a numbers perspective: VC funding in the state dropped from $95.3M in 2012 to $35.9M. (Here’s

Read More

Early Stage Biotech Investing in Wisconsin: Hot or Not?

In this post, I want to look at funding, particularly via angel investing, of Wisconsin biotech companies over the last few years. On the national scene, Bruce Booth of Atlas Venture suggested in early 2013 that the number of new biotech startups is down and “worth watching closely”. In March, Luke Timmerman of Xconomy wrote

Read More

WI VC Investment: Down (& Out?) in Q3 ’13

The venture capital investment numbers are out for the Q3 2013 (courtesy of NVCA & PwC). I am usually not particularly interested in the quarterly fluctuations but the Wisconsin numbers caught my eye, particularly relative to the national data. National VC Environment The national data across industries puts investment from Q1 to Q3 in 2013 at $20.7B, which compares favorably

Read More

Engineering Capital Flow: Thoughts on Wisconsin & Beyond

Late last month there was a formal announcement of a new $30 million information technology venture capital fund in the state of Wisconsin called 4490 Ventures. The fund is the creation of the State of Wisconsin Investment Board (SWIB) and the Wisconsin Alumni Research Foundation (WARF). The fund will be seed stage, investing $0.5 to

Read More